Predictability of Sustained Virological Response (SVR) in Patients with HCV/HIV Co-infection During Combination Therapy With Peginterferon Alfa-2A (40KD) (PEGASYS~R) Plus Ribavirin (COPEGUS~R) in the APRICOT Trial

摘要

Immunocompetent patients with HCV mono-infection who do not have an early virological response (EVR) after 12 weeks of PEGASYS/ COPEGUS therapy are highly unlikely to develop an SVR at the end of follow-up (negative predictive value [NPV] = 97%; NEJM 2002;347:975). We determined whether this applies to HCV/HIV co-infected patients enrolled in APRICOT, a randomized, partially-blinded, international trial that was recently completed.